Indeed, we further demonstrated that pharmacological inhibition of TRPC4 significantly prevented NTG-evoked cutaneous mechanical hypersensitivity and increased plasma levels of migraine-linked neuropeptide CGRP. The gene discussed is TRPC4; the disease is migraine disorder.